Metabolic: Euglycemic DKA The risk of euglycemic DKA is very uncommon, but its a clinically important and real complication to be aware of in patients using GLP-1 agonists
In the emergency department or clinical setting, treatment typically includes intravenous fluid resuscitation for dehydration, antiemetic medications to control nausea and vomiting (with careful consideration of electrolyte status when using medications like ondansetron, which may prolong QT interval in patients with hypokalemia or hypomagnesemia), and monitoring of vital signs and metabolic parameters
Dispose of used needles in a sharps container or heavy-duty plastic bottle with a puncture-resistant lid
The significance of this topic is underscored by the increasing prevalence of obesity and type 2 diabetes worldwide
C., Kashkouli, A., Liu, Z
Visceral fat, which wraps around organs and increases metabolic risk, dropped more in the treatment group compared to placebo